Carotid intima-media thickness in psoriatic arthritis: Differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 3, 2011, Pages 705-712

  Di Minno, Matteo Nicola Dario ^a   Iervolino, Salvatore ^a   Peluso, Rosario ^a   Scarpa, Raffaele ^a   Di Minno, Giovanni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

atherosclerosis; inflammation; intima media thickness; psoriatic arthritis; tumor necrosis factor

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTICLE; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CAROTID INTIMA MEDIA THICKNESS; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RISK FACTOR; TREATMENT DURATION;

ADULT; ANALYSIS OF VARIANCE; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CAROTID ARTERY DISEASES; CAROTID ARTERY, COMMON; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; ITALY; LINEAR MODELS; MALE; MIDDLE AGED; PROPENSITY SCORE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; TUNICA INTIMA; TUNICA MEDIA; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 79952189276     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.214585     Document Type: Article

References (33)

1. Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor-β blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther. 2009;22:61-73.
2. Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol. 2010;30:1014-1026.
3. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome: a crosssectional study. Dermatology. 2008;216:152-155. (Pubitemid 351158580)
4. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321-328.
5. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112:3337-3347. (Pubitemid 43739380)
6. Reusch JEB. Current concepts in insulin resistance, type 2 diabetes mellitus and the metabolic syndrome. Am. J. Cardiol. 2002;90(5A): 19G-26G.
7. Sjogren P, Basu S, Rosell M, Silveira A, de Faire U, Vessby B, Hamsten A, Hellenius M, Fisher RM. Measures of oxidized low-density lipoprotein and oxidative stress are not related and not elevated in otherwise healthy men with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2005; 25:2580-2586. (Pubitemid 43732282)
8. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "highgrade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957-2963.
9. Sethi J, Hotamisligil GS. The role of TNF α in adipocyte metabolism. Semin Cell Dev Biol. 1999;10:19-29.
10. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195-2200. (Pubitemid 36629866)
11. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459-467. (Pubitemid 46184197)
12. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57:287-293. (Pubitemid 47164092)
13. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57: 1074-1080. (Pubitemid 47237336)
14. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-2673. (Pubitemid 44205029)
15. Scarpa R, Peluso R, Atteno M, Manguso F, Spanò A, Iervolino S, Di Minno MND, Costa L, Del Puente A. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol. 2008;27: 823-826.
16. Salvarani C, Pipitone N, Catanoso MG. Clinical assessment in psoriatic arthritis. Reumatismo 2007;59(suppl 1):68-72.
17. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3: 55-78.
18. Kavanaugh AF, Ritchlin CT, and the GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006;33:1417-1421. (Pubitemid 44025162)
19. Salvarani C, Olivieri I, Pipitone N, Cantini F, Marchesoni A, Punzi L, Scarpa R, Matucci-Cerinic M; Italian Society for Rheumatology. Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-α blocking) agents in the treatment of psoriatic arthritis. Clin Exp Rheumatol. 2006;24:70-78.
20. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48-53.
21. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
22. Ashwell M, Chinn S, Stalley S, Garrow JS. Female fat distribution: a simple classification based on two circumference measurements. Int J Obes. 1982;6:143-152. (Pubitemid 12149343)
23. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281. (Pubitemid 28466823)
24. Ekundayo OJ, Markland A, Lefante C, Sui X, Goode PS, Allman RM, Ali M, Wahle C, Thornton PL, Ahmed A. Association of diuretic use and overactive bladder syndrome in older adults: a propensity score analysis. Arch Gerontol Geriatr. 2009;49:64-68.
25. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med. 1998;338:1650-1656. (Pubitemid 28267909)
26. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-2272. (Pubitemid 38924405)
27. Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, Keenan G, Burmester G, Furst DE, Weisman MH, Kalden JR, Smolen J, van der Heijde D. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65:1038-1043. (Pubitemid 44133266)
28. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279-3289. (Pubitemid 41447111)
29. Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Béchir M, Spieker LE, Neidhart M, Michel BA, Gay RE, Lüscher TF, Gay S, Ruschitzka F. Anti-tumor necrosis factor-β treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002;106:2184-2187. (Pubitemid 35222210)
30. Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum. 2007;56:831-839. (Pubitemid 46399431)
31. Schork MA. Publication bias and meta analysis. J Hypertens. 2003;21: 243-245. (Pubitemid 36269687)
32. Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, van der Meer JW, van Riel PL, Stalenhoef AF, Barrera P. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis. 2007;66:1503-1507. (Pubitemid 350032660)
33. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577-581. (Pubitemid 32179609)